BioCentury
BioCentury
ARTICLE | Emerging Company Profile

Arch-backed Neumora: using data tools for precision neuroscience

By Paul Bonanos, Associate Editor
October 7, 2021 10:33 AM UTC

Deep-pocketed Arch, partner Amgen back Neumora’s eight-program pipeline in neuroscience



Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Arch Venture Partners

Neumora Therapeutics Inc.

BCIQ Target Profiles

Kappa opioid receptor (KOR) (OPRK1)

Vasopressin 1a (V1a) receptor

Serotonin receptor 2A (5-HT2A) (HT2RA)

NMDA receptor NR2A subtype (GRIN2A) (NR2A)

NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B)

Casein kinase 1 (CSNK1) (CKI)

Glucosylceramidase beta (GBA; GCase)

BCIQ Company Profiles

Arch Venture Partners

Neumora Therapeutics Inc.

BCIQ Target Profiles

Kappa opioid receptor (KOR) (OPRK1)

Vasopressin 1a (V1a) receptor

Serotonin receptor 2A (5-HT2A) (HT2RA)

NMDA receptor NR2A subtype (GRIN2A) (NR2A)

NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B)

Casein kinase 1 (CSNK1) (CKI)

Glucosylceramidase beta (GBA; GCase)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS